General health status of Dutch elderly receiving implant-retained overdentures
Bakker, Mieke H; Vissink, Arjan; Raghoebbar, Gerry M; Visser, Anita

Published in:
Clinical Implant Dentistry and Related Research

DOI:
10.1111/cid.12984

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Bakker, M. H., Vissink, A., Raghoebbar, G. M., & Visser, A. (2021). General health status of Dutch elderly receiving implant-retained overdentures: A 9-year big data cross-sectional study. Clinical Implant Dentistry and Related Research, 23(2). Advance online publication. https://doi.org/10.1111/cid.12984
General health status of Dutch elderly receiving implant-retained overdentures: A 9-year big data cross-sectional study

Mieke H. Bakker DDS, MSc1 | Arjan Vissink DDS, MD, PhD1 | Gerry M. Raghoebabar DDS, MD, PhD1 | Anita Visser DDS, PhD1,2

1Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2Department of Gerodontology, Dental School, Center for Dentistry and Oral Hygiene, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Correspondence
Mieke H. Bakker, DDS, MSc, Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, PO Box 30.001, NL-9700 RB Groningen, The Netherlands. Email: m.h.bakker@umcg.nl

Funding information
Dutch Association of Oral Implantology (NVOI)
NVOI Stipendium 2017; Nederlands Tijdschrift voor Tandheelkunde (NTvT)
Lustrumonderzoeksbeurs 2018

Abstract
Background: Very little information is available on the general health of elderly who are provided with an implant-retained overdenture (IOD).

Purpose: The general health status of three groups of elderly (≥75 years) were compared: those with a natural dentition (ND), those treated with an implant-retained overdenture (IOD), and those wearing a conventional denture (CD).

Materials and methods: Data on healthcare costs were obtained from records of Dutch health insurers that are collected by Vektis. Data on general health (chronic diseases, medication use, and polypharmacy) were acquired for elderly patients with a ND, an IOD, and a CD in 2009 and 2017. Data on the general health of elderly who received an IOD were also acquired from 2010 through 2016.

Results: On average, the general health of elderly who received an IOD was comparable to general health of elderly with a ND and was better than the general health of elderly with a CD (lower prevalence of diabetes, cardiac disease, and hypertension). The general health profile of elderly receiving an IOD was consistent during all years.

Conclusions: The general health of elderly with a ND or IODs is better than those with CDs.

KEYWORDS aging, big data, cross-sectional study, dental implants, elderly, general health, implant-retained overdenture

1 INTRODUCTION

Edentulous patients often experience functional and psychosocial problems related to their conventional dentures (CD) due to an impaired load-bearing capacity and poor retention. Placing dental implants to retain a removable overdenture is regarded the first choice of treatment for resolving such denture-related problems.1,2 Placing implants to retain an overdenture is regarded a safe, reliable treatment option with high survival rates (>95%), even in studies with a follow-up up to 20 years.3-5 Moreover, mandibular implant-retained overdentures (IOD) show better retention and stability than CDs, thereby enhancing chewing ability and bite force.6,7 This has a positive effect on patient satisfaction and quality of life,6-11 resulting in a cost-effective treatment strategy, despite the high fabrication

Received: 10 July 2020 Revised: 18 December 2020 Accepted: 11 January 2021
DOI: 10.1111/cid.12984

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. Clinical Implant Dentistry and Related Research Published by Wiley Periodicals LLC.

Clin Implant Dent Relat Res. 2021;1–8.
wileyonlinelibrary.com/journal/cid
costs. In line with the increased oral function and patient satisfaction, improvements in nutritional status, social wellbeing, and eventually general health can be expected as well.

Although many studies have been published on oral functioning of patients with IODs, data on the relationship between IOD treatment and general health and nutritional status remains scarce. Previous studies on nutritional status suggested that IODs have a positive effect on nutritional status, but no conclusive evidence is available yet. Thus far, only one study focused on the impact of IODs on general health in elderly. This cross-sectional study showed that community-dwelling elderly wearing an IOD reported less frailty, better general health, and better physical function than elderly wearing CDs. This difference in health status between IOD and CD wearers was studied in elderly ≥75 years of age. Although the results of that study suggest that elderly with an IOD have better general health on average than elderly with CDs, it is hard to draw definitive conclusions, as we do not know if these differences are already present when the dental implants are placed. Therefore, the aim of our study was to assess the general health status of edentulous elderly (≥75 years) at the time that they received an IOD as well as to compare their health status with the health status of edentulous elderly with a CD or ND. The general health status of these three groups in 2009 was compared with the health status of matching groups in 2017. Additionally, the health status of new IOD wearers was assessed annually between 2010 and 2016 to determine whether the average health status of new IOD wearers was consistent over a longer period as well as to determine whether there were age-related differences between elderly aged 75-85 and ≥85 years.

2 | MATERIALS AND METHODS

This study was performed in collaboration with Vektis, an organization that warehouses the data on all health care declarations in the Netherlands.

2.1 | Health status of elderly with a natural dentition, conventional denture, or implant-retained overdenture

Three groups of elderly (≥75 years) were distinguished by oral status: elderly with a ND, edentulous elderly who received a CD (first or replaced denture), and elderly who were treated with dental implants to support an IOD. The latter two groups of elderly received the corresponding dental treatments in 2009 or 2017. All groups were categorized by oral status based on dental insurance declarations recorded in the Vektis database.

For these three groups the following variables were collected:

- Medical conditions: Asthma, cancer, high cholesterol, diabetes, cardiac disease, hypertension, kidney disease, Parkinson’s disease, and rheumatoid arthritis. The diagnosis was based on prescribed medication derived from a pharmacy-based cost group model; the use of a specific type of prescribed medication was used as a marker for chronic conditions.
- Medication use: The following types of medications for elderly patients were recorded: antithrombotics, bisphosphonates, inhalation corticosteroids, antihypertensives, and antidepressants. The use of five or more medications (polypharmacy) of the previously described drugs was also recorded.
- Socioeconomic status (SES) by municipality of residence: SES was based on data provided by the Netherlands Institute for Social Research. Variables to determine SES were the average income, percentage of individuals with low income, percentage of individuals with low education level, and percentage of unemployed individuals. Based on the SES scores, municipalities were ranked into three groups: the 30% of municipalities with the lowest scores were ranked as low SES, the 30% with the highest scores were ranked as high SES, and the remaining 40% were ranked as middle SES.

2.2 | Health status of elderly treated with implant-retained overdentures between 2009 and 2017

To assess whether the results of the elderly with IODs in 2009 and 2017 were not coincidental, Vektis collected data on the health status of elderly that received an IOD between 2010 and 2016. Between 2009 and 2016 all elderly who received an IOD were assessed annually. To identify possible age-related differences between elderly receiving IODs, two subgroups based on age were formed (75-85 years and ≥85 years).

2.3 | Statistics

Descriptive statistics were used to report prevalence of chronic diseases, polypharmacy, medication use, and SES. Statistical differences were calculated between elderly with different oral status using Chi-square tests. Chi-square tests were also used to determine statistically significant differences over time (2009-2017) between “younger” (75-85 years) and “older” (85 years and over) elderly receiving an IOD. SPSS IBM Statistics version 23.0 (SPSS, Chicago, Illinois) was used for statistical analysis of the results.
3.1 Oral status: Natural dentition, conventional denture, or IOD

Table 1 presents demographic characteristics, chronic conditions, medication use and healthcare consumption of elderly categorized by oral status. Almost all variables were statistically significant between the groups with different oral health status, which is a consequence of the large study population (>100 000 elderly). This often results in statistically significant outcome that may not be clinically relevant. Therefore, we focused on clinically relevant differences between groups, defined as ≥5% difference in prevalence.

Elderly with IODs were more frequently aged between 75 and 85 than elderly with a ND or CD. Also, elderly with IODs or CD had more frequently low SES than elderly with a ND. With regard to systemic disease, clear differences were found in the prevalence of cardiac disease, hypertension, and diabetes between the groups. Elderly with CDs had higher prevalence of cardiac disease (Figure 1), hypertension (Figure 2), and diabetes (Figure 3) than elderly with a ND or IODs. Furthermore, polypharmacy, and the use of antithrombotic and antihypertensive drugs was highest in elderly with CDs.
3.2 | Health status of elderly treated with an IOD between 2009 and 2017

Characteristics of elderly who received IODs between 2009 and 2017 are shown in Table 2. Implants are mostly (90%) placed in elderly before the age of 85. Medication use and the presence of chronic health conditions of elderly aged 75-85 and over 85 corresponded with these variables in the general aging population with the exception of diabetes and high cholesterol. The prevalence of diabetes was lower among elderly over 85 who received an IOD.

4 | DISCUSSION

The general health of elderly who received an IOD and elderly with a ND appears to be better than patients wearing CDs. In our study, this finding was fairly consistent over time. Placing dental implants to support an IOD is a more common treatment in elderly between 75 and 85 than in elderly aged ≥85 years. Common general health conditions such as cardiac disease, hypertension, and diabetes are less prevalent among elderly patients receiving dental implants to retain an IOD than patients wearing CDs.

This 9-year cross-sectional study confirmed the observations of Hoeksema and colleagues that elderly with a ND and elderly who received an IOD had better general health on average than elderly wearing CDs. At least part of this difference in general health status between these two groups is probably because the average age of elderly who received an IOD for the first time was lower on average than that of CD wearers. However, it is still unknown whether this positive difference continues over time or the average general health of IOD wearers gradually approaches that of CD wearers. This is an issue that requires further research.

With regard to conditions affecting general health, the prevalence of cardiac disease and hypertension was lower on average in elderly with a ND and IOD wearers than in CD wearers. In elderly with a ND or IOD, the prevalence figures for cardiac disease and hypertension were within the same range as prevalence figures for these diseases in the general population in the Netherlands, while compared with the general population the prevalence of diabetes was significantly lower in elderly who were provided with an IOD. However, diabetes was less prevalent in elderly who received an IOD than in the general elderly population. The overall prevalence of diabetes in Dutch elderly (≥75 years) is about 25%, while in our study the prevalence in elderly who received an IOD was 5%-14%, and was lowest in the very old. A possible explanation for this discrepancy is that patients or their caregivers were more reluctant about implant placement in diabetic elderly. This might be due to the general belief that the risk of implant failure is higher in diabetic subjects due to impaired wound healing, despite a recent study showing that controlled diabetes should not be regarded as a contraindication for implant placement.

A limitation of the study is the potential bias with regard to the inclusion of elderly with a ND; this figure was lower than would have been expected for the general population in Netherlands. This discrepancy is inherent to the Vektis database, which contains all the insured primary and specialist healthcare costs in the Netherlands. Most of the costs (>90% of each treatment) of CDs and IOD treatment are covered by obligatory healthcare insurance, while for elderly with a ND, most dental treatment costs are not covered by this
## Table 2: SES, prevalence of chronic conditions and medication use in Dutch citizens (75-85 years and ≥85 years) receiving IODs in the period 2009-2017

|                  | 2009 |         | 2010 |         | 2011 |         | 2012 |         | 2013 |         |
|------------------|------|---------|------|---------|------|---------|------|---------|------|---------|
|                  | 75-85 | ≥85     | 75-85 | ≥85     | 75-85 | ≥85     | 75-85 | ≥85     | 75-85 | ≥85     |
| SES              | N = 5045 (92%) | N = 413 (8%) | P-value | N = 4584 (91%) | N = 462 (9%) | P-value | N = 5167 (90%) | N = 544 (10%) | P-value | N = 3883 (92%) | N = 357 (8%) | P-value | N = 4424 (91%) | N = 460 (9%) | P-value |
| Socioeconomic status |     |         |     |         |     |         |     |         |     |         |     |         |     |         |     |         |
| Low              | 1388 (28%) | 125 (30%) | 0.229 | 1388 (28%) | 125 (30%) | 0.229 | 1408 (27%) | 151 (28%) | 0.800 | 1243 (27%) | 133 (29%) | 0.442 | 1388 (28%) | 125 (30%) | 0.229 |
| Middle           | 2151 (43%) | 169 (41%) | 0.498 | 1995 (44%) | 175 (38%) | 0.200 | 2184 (42%) | 228 (42%) | 0.873 | 1738 (45%) | 123 (34%) | 0.001 | 1935 (44%) | 186 (40%) | 0.174 |
| High             | 1506 (30%) | 119 (29%) | 0.657 | 1346 (29%) | 154 (33%) | 0.075 | 1575 (30%) | 165 (30%) | 0.942 | 1173 (30%) | 122 (34%) | 0.001 | 1393 (31%) | 143 (31%) | 0.860 |
| Chronic conditions |     |         |     |         |     |         |     |         |     |         |     |         |     |         |     |         |
| Asthma           | 234 (5%) | 15 (4%) | 0.346 | 216 (5%) | 18 (4%) | 0.427 | 265 (5%) | 20 (4%) | 0.139 | 187 (5%) | 18 (5%) | 0.849 | 198 (4%) | 14 (4%) | 0.151 |
| Cancer           | -    | -      | -    | -      | -    | -      | -    | -      | -    | -      | -    | -      | -    | -      |
| Cardiac disease  | 695 (14%) | 90 (22%) | ≤0.001 | 651 (14%) | 96 (21%) | ≤0.001 | 688 (13%) | 136 (21%) | ≤0.001 | 512 (13%) | 83 (23%) | ≤0.001 | 578 (12%) | 100 (18%) | ≤0.001 |
| Diabetes         | 575 (11%) | 34 (8%) | 0.050 | 497 (11%) | 34 (7%) | 0.020 | 639 (12%) | 51 (7%) | 0.424 | 479 (12%) | 24 (7%) | 0.002 | 574 (11%) | 39 (5%) | 0.006 |
| High cholesterol | 897 (18%) | 31 (8%) | 0.001 | 829 (18%) | 48 (10%) | ≤0.001 | 1022 (20%) | 68 (10%) | ≤0.001 | 821 (21%) | 53 (15%) | 0.005 | 959 (19%) | 70 (12%) | 0.001 |
| Hypertension     | 2630 (52%) | 203 (49%) | 0.225 | 2473 (54%) | 241 (52%) | 0.020 | 2842 (55%) | 301 (52%) | 0.884 | 2166 (56%) | 188 (53%) | 0.256 | 2423 (49%) | 269 (41%) | 0.128 |
| Kidney disease   | 18 (<1%) | 9 (2%) | 0.001 | 19 (<1%) | 9 (2%) | 0.001 | 18 (<1%) | 9 (2%) | 0.001 | 16 (<1%) | 9 (2%) | 0.001 | 16 (<1%) | 9 (2%) | 0.001 |
| Parkinson's disease | 52 (1%) | 9 (2%) | 0.325 | 52 (1%) | 9 (2%) | 0.325 | 52 (1%) | 9 (2%) | 0.325 | 52 (1%) | 9 (2%) | 0.325 | 52 (1%) | 9 (2%) | 0.325 |
| Rheumatoid arthritis | 35 (1%) | -      | -    | 60 (1%) | 9 (2%) | 0.018 | 55 (1%) | 9 (2%) | 0.214 | 44 (1%) | 9 (3%) | 0.082 | 78 (1%) | 9 (2%) | 0.765 |
| Prescribed medication |     |         |     |         |     |         |     |         |     |         |     |         |     |         |     |         |
| Antithrombotics  | 2302 (46%) | 195 (47%) | 0.534 | 2147 (47%) | 220 (48%) | 0.748 | 2373 (46%) | 327 (60%) | ≤0.001 | 1824 (47%) | 198 (55%) | ≤0.001 | 2049 (46%) | 254 (55%) | ≤0.001 |
| Bisphosphonates  | 519 (10%) | 47 (11%) | 0.484 | 477 (10%) | 61 (13%) | 0.063 | 469 (9%) | 65 (12%) | 0.029 | 366 (9%) | 38 (11%) | ≤0.001 | 396 (9%) | 49 (11%) | 0.978 |
| Inhaled corticosteroids | 687 (14%) | 53 (14%) | 0.654 | 608 (13%) | 50 (11%) | 0.138 | 725 (14%) | 73 (13%) | 0.695 | 531 (14%) | 39 (11%) | 0.357 | 592 (13%) | 52 (11%) | 0.210 |
| Antihypertensives | 2973 (59%) | 257 (62%) | 0.190 | 2850 (62%) | 289 (63%) | 0.872 | 3233 (63%) | 386 (71%) | ≤0.001 | 2423 (62%) | 231 (65%) | ≤0.001 | 2692 (61%) | 303 (66%) | 0.035 |
| Antidepressants  | 354 (11%) | 47 (11%) | 0.614 | 510 (11%) | 54 (12%) | 0.714 | 545 (11%) | 61 (11%) | 0.632 | 430 (11%) | 51 (14%) | ≤0.001 | 514 (12%) | 61 (13%) | 0.298 |
| Polyparmacy      | 431 (9%) | 35 (8%) | 0.241 | 423 (9%) | 40 (9%) | 0.686 | 468 (9%) | 65 (12%) | 0.027 | 378 (10%) | 44 (12%) | 0.473 | 389 (9%) | 41 (9%) | 0.931 |

(Continues)
|                   | 2014 | 2015 | 2016 | 2017 |
|-------------------|------|------|------|------|
|                   | 75-85 | ≥85  | 75-85 | ≥85  | 75-85 | ≥85  | 75-85 | ≥85  |
|                   | N = 4305 (90%) | N = 472 (10%) | P-value | N = 4080 (90%) | N = 474 (10%) | P-value | N = 4873 (91%) | N = 511 (9%) | P-value | N = 4230 (91%) | N = 401 (9%) | P-value |
| Chronic diseases  |      |      |      |      |      |      |      |      |      |      |      |      |      |
| Asthma            | 205 (5%) | 20 (4%) | 0.610 | 191 (5%) | 15 (3%) | 0.133 | 215 (4%) | 30 (6%) | 0.132 | 202 (5%) | 20 (5%) | 0.849 |
| Cancer            | -     | -    | ≤0.001 | -     | -    | ≤0.001 | 9 (<1%) | 9 (2%) | ≤0.001 | 18 (<1%) | -    | 0.396 |
| Cardiac disease   | 546 (13%) | 99 (21%) | ≤0.001 | 498 (12%) | 97 (20%) | ≤0.001 | 555 (11%) | 120 (23%) | ≤0.001 | 454 (11%) | 67 (17%) | ≤0.001 |
| Diabetes          | 524 (12%) | 35 (7%) | 0.002 | 503 (12%) | 32 (7%) | ≤0.001 | 681 (14%) | 49 (10%) | 0.006 | 547 (13%) | 45 (11%) | 0.327 |
| High cholesterol  | 1019 (24%) | 66 (14%) | ≤0.001 | 1016 (25%) | 78 (16%) | ≤0.001 | 1252 (26%) | 92 (18%) | ≤0.001 | 1081 (26%) | 77 (19%) | 0.005 |
| Hypertension      | 2347 (55%) | 261 (55%) | 0.747 | 2195 (54%) | 248 (52%) | 0.541 | 2726 (56%) | 274 (54%) | 0.315 | 2265 (54%) | 198 (50%) | 0.110 |
| Kidney disease    | 9 (<1%) | 9 (2%) | ≤0.001 | 10 (<1%) | -    | 0.613 | 17 (<1%) | 9 (2%) | ≤0.001 | 18 (<1%) | 18 (5%) | ≤0.001 |
| Parkinson's disease | 60 (1%) | 9 (2%) | 0.375 | 51 (1%) | 9 (2%) | 0.241 | 68 (1%) | 9 (2%) | 0.508 | 52 (1%) | 18 (5%) | ≤0.001 |
| Rheumatoid arthritis | 50 (1%) | 9 (2%) | 0.164 | 56 (1%) | 9 (2%) | 0.361 | 62 (1%) | 9 (2%) | 0.357 | 65 (2%) | 9 (2%) | 0.280 |
| Prescribed medication |      |      |      |      |      |      |      |      |      |      |      |      |      |
| Antithrombotics   | 2017 (47%) | 264 (56%) | ≤0.001 | 1890 (46%) | 257 (54%) | 0.001 | 2318 (48%) | 300 (59%) | ≤0.001 | 2033 (48%) | 222 (55%) | 0.005 |
| Bisphosphonates   | 348 (8%) | 37 (8%) | 0.853 | 304 (7%) | 37 (8%) | 0.781 | 313 (6%) | 38 (7%) | 0.377 | 227 (5%) | 21 (5%) | 0.912 |
| Inhaled corticosteroids | 552 (13%) | 64 (14%) | 0.650 | 523 (13%) | 43 (9%) | 0.019 | 603 (12%) | 75 (15%) | 0.136 | 526 (12%) | 44 (11%) | 0.394 |
| Antihypertensives | 2648 (62%) | 306 (65%) | 0.159 | 2518 (62%) | 306 (65%) | 0.228 | 3082 (63%) | 344 (67%) | 0.169 | 2548 (60%) | 249 (62%) | 0.467 |
| Antidepressants   | 495 (11%) | 45 (10%) | 0.201 | 475 (12%) | 54 (11%) | 0.872 | 611 (13%) | 58 (11%) | 0.439 | 504 (12%) | 45 (11%) | 0.682 |
| Polypharmacy      | 398 (9%) | 47 (10%) | 0.613 | 366 (9%) | 54 (11%) | 0.085 | 429 (9%) | 58 (11%) | 0.056 | 367 (9%) | 29 (7%) | 0.323 |

*P-value <0.05, determined between two subgroups (elderly aged 75-85 and aged 85 and over).
insurance. Patients can optionally acquire supplementary insurance to cover their dental costs, but not all patients do so. Because Vektis only records dental costs that are reimbursed by obligatory or supplementary insurance, elderly without dental insurance are not included in the database. This leads to a lower number of elderly with a ND in the database than in the general population. A possible explanation of this discrepancy is that the general health of elderly with a ND and without dental insurance may be better than the health of those with a ND and with dental insurance. As a result, elderly with reasonable dental health, and often better general health, may decide not to pay for supplementary dental insurance, and would therefore be excluded from the Vektis database.

As a consequence of this big data study most outcomes are statistically significant, but not all are also clinically meaningful. This is a common issue with big data studies. There has been some debate in observational studies with big data which differences have actually value for clinical practice. Clinical significance is defined as the smallest meaningful change in an observed effect but this is not defined as a standard value. Therefore, in this study we focused on clinically meaningful differences between elderly patients.

We conclude that the general health of elderly with a ND or with an IOD is better on average than the general health of elderly with CDs. Our study also shows that IOD treatment is more often done in elderly 75-85 years than those ≥85 years. Although our study indicates that the health status of elderly with IODs (lower prevalence of diabetes, cardiac disease, and hypertension) is consistently better at the moment of implant placement than that of elderly with CDs, future studies should be performed to determine whether this difference continues over the long term, or whether the general health of these groups tends to converge.

ACKNOWLEDGMENTS
We would like to thank Vektis for the data processing, Dr A.R. Hoeksema, geriatric dentist, for his support in the initial stages of this study and C. Frink for language editing.

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS
Mieke H. Bakker: Concept/design, data analysis/interpretation, drafting article, statistics, approval of article. Arjan Vissink: Concept/design, drafting article, critical revision of article, approval of article. Gerry M. Raghoebar: Concept/design, critical revision of article, approval of article. Anita Visser: Concept/design, drafting article, critical revision of article, approval of article.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Mieke H. Bakker @ https://orcid.org/0000-0002-5968-3163
Anita Visser @ https://orcid.org/0000-0002-8676-2334

REFERENCES
1. Feine JS, Carlsson GE, Awad MA, et al. The McGill consensus statement on overdentures. Mandibular two-implant overdentures as first choice standard of care for edentulous patients. Gerodontology. 2002; 19(1):3-4. https://doi.org/10.1111/j.1741-2358.2002.00003.x.
2. Thomason JM, Feine J, Exley C, et al. Mandibular two-implant-supported overdentures as the first choice standard of care for edentulous patients—the York consensus statement. Br Dent J. 2009;207(4):185-186. https://doi.org/10.1038/sbjdj.2009.728.
3. Srinivasan M, Meyer S, Mombelli A, Müller F. Dental implants in the elderly population: a systematic review and meta-analysis. Clin Oral Implants Res. 2017;28(8):920-930. https://doi.org/10.1111/clr.12898.
4. Verbruggen M, Marcelis K, Couwke W, Naert I, Quirynen M. Long-term, retrospective evaluation (implant and patient-centered outcome) of the two-implants-supported overdenture in the mandible. Part 1: survival rate. Clin Oral Implants Res. 2010;21(4):357-365. https://doi.org/10.1111/j.1600-0501.2009.01849.x.
5. Bakker MH, Vissink A, Meijer HJA, Raghoebar GM, Visser A. Mandibular implant-supported overdentures in frail elderly: a prospective study with 20-year follow-up. Clin Implant Dent Relat Res. 2019;21(4):586-592. https://doi.org/10.1111/cid.12772.
6. Allen PF, McMillan AS. A longitudinal study of quality of life outcomes in older adults requesting implant prostheses and complete removable dentures. Clin Oral Implants Res. 2003;14:173-179.
7. Awad MA, Lund JP, Shapiro SH, et al. Oral health status and treatment satisfaction with mandibular implant overdentures and conventional dentures: a randomized clinical trial in a senior population. Int J Prosthodont. 2003;16(4):390-396.
8. Thomason JM, Lund JP, Chehade A, Feine JS. Patient satisfaction with mandibular implant overdentures and conventional dentures 6 months after delivery. Int J Prosthodont. 2003;16:467-473.
9. Sivaramakrishnan G, Sridharan K. Comparison of implant supported mandibular overdentures and conventional dentures on quality of life: a systematic and meta-analysis of randomized controlled studies. Aust Dent J. 2016;61(4):482-488. https://doi.org/10.1111/adj.12416.
10. Boven GC, Speksnijder CM, Meijer HJA, Vissink A, Raghoebar GM. Masticatory ability improves after maxillary implant overdenture treatment: a randomized controlled trial with 1-year follow-up. Clin Implant Dent Relat Res. 2019;21(2):369-376. https://doi.org/10.1111/cid.12721.
11. Zembic A, Wismeijer D. Patient-reported outcomes of maxillary implant-supported overdentures compared with conventional dentures. Clin Oral Implants Res. 2014;25(4):441-450. https://doi.org/10.1111/cid.12169.
12. Kutkut A, Bertoli E, Frazer R, Pinto-Sinali G, Fuentealba Hidalgo R, Studts J. A systematic review of studies comparing conventional complete denture and implant retained overdenture. J Prosthodont Res. 2018;62(1):1-9. https://doi.org/10.1016/j.jpor.2017.06.004.
13. Heydecke G, Penrod JR, Takanashi Y, Lund JP, Feine JS, Thomsaon JM. Cost-effectiveness of mandibular two-implant overdentures and conventional dentures in the edentulous elderly. J Dent Res. 2005;84(9):794-799. https://doi.org/10.1177/15408590508400903.
14. Müller F, Duverney E, Loup A, Vazquez L, Herrmann FR, Schimmel M. Implant-supported overdentures in very old adults: a randomized controlled trial. J Dent Res. 2013;92(12 suppl):1545S-160S. https://doi.org/10.1177/0022034513509630.
15. Morais JA, Heydecke G, Pawlik J, Lund JP, Feine JS. The effects of mandibular two-implant overdentures on nutrition in elderly edentulous individuals. J Dent Res. 2003;82(1):53-58. https://doi.org/10.1177/154405910308200112.
16. Awad MA, Morais JA, Wollin S, Khalil A, Gray-Donald K, Feine JS. Mandibular overdentures and nutrition. A randomized controlled trial. J Dent Res. 2012;91(1):39-46. https://doi.org/10.1177/0022034511423396.
17. Yamazaki T, Martiniuk AL, Irie K, Sokejima S, Lee CM. Does a mandibular overdenture improve nutrient intake and markers of nutritional...
status better than a conventional complete denture? A systematic review and meta-analysis. *BMJ Open*. 2016;6(8):e011799. https://doi.org/10.1136/bmjopen-2016-011799.

18. Hoeksema AR, Spoorenberg S, Peters LL, et al. Elderly with remaining teeth report less frailty and better quality of life than edentulous elderly: a cross-sectional study. *Oral Dis*. 2017;23(4):526-536. https://doi.org/10.1111/odi.12644.

19. Lamers LM, Van Vliet RCJA. The pharmacy-based cost group model: validating an adjusting the classification of medications for chronic conditions to the Dutch situation. *Health Policy*. 2004;68(1):113-121. https://doi.org/10.1016/j.healthpol.2003.09.001.

20. Kaplan RM, Chambers DA, Phil D, Glasgow RE. Big data and large sample seize: a cautionary note on the potential for bias. *Clin Transl Sci*. 2014;7(4):342-346. https://doi.org/10.1111/cts.12178.

21. Volksgezondheidenzorg.info. Subjects studied: hartfalen, diabetes, bloeddruk). RIVM: Bilthoven. https://www.volksgezondheidenzorg.info/onderwerpen. Accessed February 4, 2020.

22. Vissink A, Spijkervet FKL, Raghoebbar GM. The medically compromised patient: are dental implants a feasible option? *Oral Dis*. 2018;24(1–2):253-260. https://doi.org/10.1111/odi.12762.

23. Goodin A, Decher C, Valenzuela C, et al. The power and pitfalls of big data research in obstetrics and gynecology: a consumer’s guide. *Obstet Gynecol Surv*. 2017;72(11):669-682. https://doi.org/10.1097/OGX.0000000000000504.

How to cite this article: Bakker MH, Vissink A, Raghoebbar GM, Visser A. General health status of Dutch elderly receiving implant-retained overdentures: A 9-year big data cross-sectional study. *Clin Implant Dent Relat Res*. 2021;1–8. https://doi.org/10.1111/cid.12984